• Avisi Technologies

  Participated · Series A · Feb 2026

  Avisi Technologies, Inc. is a clinical-stage company focused on creating novel ophthalmic solutions, most notably VisiPlate®, an investigational aqueous shunt engineered from an ultrathin, patented metamaterial designed to maintain intra-ocular pressure through multiple microchannels that resist blockage and scarring. The device targets the unmet need for long-term, low-maintenance glaucoma care and is currently being evaluated in the FDA IDE-approved SAPPHIRE pivotal trial that is enrolling patients across the United States. Avisi’s broader pipeline includes V-001, a sustained intraocular drug-delivery platform, and VisiPlate-S, a drainage device intended for use during cataract surgery. Proceeds from its latest financing will fund the SAPPHIRE trial and advance additional pipeline programs addressing the full spectrum of glaucomatous disease. The company has garnered recognition and non-dilutive support from the National Science Foundation, the Glaucoma Research Foundation, Johnson & Johnson JLABS, and other industry accelerators. Current investors include both venture funds and angel networks, underscoring diversified backing for its development roadmap. No revenue or user figures have been disclosed to date.

• Cytonus Therapeutics

  Participated · Series A · Dec 2023

  Cytonus Therapeutics is developing a proprietary Cargocyte™ Drug Delivery Platform—engineered, synthetic cell-like delivery vehicles designed to carry multiple therapeutic payloads into hard-to-reach tissues. The company has built a pipeline of proprietary immunotherapeutic products targeting cancers, infectious diseases, inflammatory diseases, and cognitive disorders. Cargocytes are described as programmable, off-the-shelf delivery drones that can selectively, potently, and controllably deliver well-validated therapies. Cytonus will use the funds from its recent financing to continue development of this portfolio and advance payload delivery to metastatic tumors and the central nervous system. The company is led by CEO Remo Moomiaie-Qajar, MD, with Chief Scientific Innovator Richard Klemke, PhD, and executive chairman Christopher Thorne, JD-MBA. In conjunction with the financing Cytonus expanded its board and scientific advisors, including additions of Jaeyeol (Jae) An, PhD, and John C. Bell, PhD.

• Toregem BioPharma

  Participated · Series A · Jul 2023

  Toregem BioPharma is developing TRG-035, an experimental antibody therapy designed to neutralize USAG-1, a protein that suppresses tooth formation, with the goal of reactivating dormant tooth buds and prompting natural tooth development. The company’s initial clinical focus is on patients with congenital tooth agenesis, with broader potential envisioned for stimulating a “third dentition” to treat tooth loss from aging, decay, or injury. Preclinical evidence of tooth regeneration has come primarily from animal studies (mice), while human testing to date has focused on safety. Toregem launched a Phase I trial at Kyoto University Hospital in October 2024 that enrolled 30 healthy adult men missing at least one molar; recruitment was reported to have stopped by March 2026 and the study is operationally complete, though full results have not been published. Toregem has secured a mix of equity financing and non-dilutive support (grants and subsidies) and reports cumulative funding above $29 million. The company is using its recent Pre-Series C proceeds to advance Phase II trials in Japan and to prepare for clinical development in the United States.

• Cellusion

  Participated · Series C · Jun 2023

  Cellusion is developing CLS001, an iPS cell-derived corneal endothelial cell substitute produced via a proprietary technique to efficiently generate corneal endothelial-like cells. The lead program, CLS001, targets bullous keratopathy and aims to address global corneal donor shortages that leave an estimated 13 million patients waiting for transplants. The company has reinforced its R&D organization and in September 2022 executed a license agreement with Celregen (a Fosun Pharma subsidiary) for operations in Greater China. In March 2023 a First In Human transplant of CLS001 was announced by joint research partner Dr. Shigeto Shimmura, and Cellusion is advancing preparations for company-sponsored clinical trials in Japan and for global trials. Proceeds from the recent fundraise will be used to advance those clinical-trial preparations and to support R&D of subsequent pipelines following CLS001. Cellusion is led by CEO Shin Hatou, is headquartered in Tokyo, was founded in January 2015, and has raised ¥4.5 billion (approximately US$33 million) in total to date. Cellusion develops CLS001, a corneal endothelial cell substitute (CECSi cells) differentiated from iPS cells, intended to treat bullous keratopathy and address the global shortage of donor corneas. The company highlights a simple injection delivery procedure designed to reduce reliance on donor tissue and specialized surgical expertise. Cellusion plans company-sponsored phase 1/2 clinical trials of CLS001 in Japan and overseas and has already obtained approval for an investigator-initiated first-in-human study at Keio University Hospital. The new funding will also be used to expand its Tokyo-based research and business teams and to advance R&D on other pipeline programs. Cellusion is pursuing supply-chain partnerships with Toho Holdings and Toyo Seikan Group Holdings to support CLS001 manufacturing and distribution. Founded in January 2015 and headquartered in Tokyo, the company aims to scale clinical development and global access to its cell therapy.

No current team members are available.